Valeant planning hostile bid for Allergan

June 17, 2014
This March 20, 2002 file photo shows a vial of Botox, made by Allergan. Valeant Pharmaceuticals on Tuesday, June 17, 2014 said it plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals. (AP Photo/Damian Dovarganes, File)

Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion.

Valeant Pharmaceuticals International Inc. Chairman and CEO J. Michael Pearson said in a conference call Tuesday that proxies seeking support for its bid may be mailed in "the near-term."

"It is clear Allergan's management and their board will never sit down and act in the interest of their shareholders," he said.

Canadian-based Valeant has teamed with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their offer several times.

Allergan Inc. has repeatedly rejected the offers as underpriced and risky. But Pearson said that Valeant believes an Allergan vote would "be overwhelmingly in support of the deal."

Valeant and Pershing—which has a 9.7 percent stake in Allergan—have continued to pursue Allergan despite the Irvine, California company's disinterest. The latest offer was worth about $53 billion. Allergan's market capitalization was about $48 billion in midday trading Tuesday.

Ackman previously said he would move to replace most of Allergan's board of directors as part of the battle for control of the company. Pearson said Tuesday that Pershing is looking to call a special shareholders meeting to remove six of Allergan's nine board members. Last week Pershing filed a lawsuit to confirm that its push for the special meeting won't trigger a defensive "poison pill" from Allergan.

Allergan adopted a one-year shareholder rights plan after Valeant and Pershing announced their bid in April. Under the plan, if any person or group acquires a 10 percent or greater stake in the company, other stock owners would be allowed to acquire additional shares at a discounted rate.

Pearson said that a special meeting of Allergan shareholders could be held in August, but should take place by year's end.

An email to Allergan for comment was not immediately returned.

Allergan's stock added $1.71, or 1.1 percent, to $161.07 in midday trading Tuesday, while shares of Valeant rose $1.95, or 1.7 percent, to $119.70.

Explore further: Allergan board rebuffs latest Valeant offer (Update)

Related Stories

Allergan board rebuffs latest Valeant offer (Update)

June 10, 2014
Allergan's board has unanimously rejected the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker said the offer isn't even worth talking about.

Canada's Valeant again ups bid for Botox maker

May 31, 2014
Canadian pharmaceutical firm Valeant on Friday upped for the second time in a week its hostile bid for Allergan, the US maker of Botox, to $53.5 billion.

Valeant Pharma plans improved offer for Allergan

May 13, 2014
Valeant Pharmaceuticals will not easily accept rejection in its bid to acquire Botox maker Allergan for nearly $46 billion.

Allergan board turns down Valeant takeover offer (Update)

May 12, 2014
Botox maker Allergan formally rejected on Monday a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and poses a significant risk to its growth prospects.

Valeant raises cash-stock offer for Allergan (Update)

May 28, 2014
Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about a deal.

Valeant, Ackman make $45.6B Allergan bid

April 22, 2014
Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

Recommended for you

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.